Abstract
The generation of a robust population of memory T cells is critical for effective vaccine and cell-based therapies to prevent and treat infectious diseases and cancer. A series of recent papers have established a new, cell-intrinsic approach in which small molecules target key metabolic and developmental pathways to enhance the formation and maintenance of highly functional CD8(+) memory T cells. These findings raise the exciting new possibility of using small molecules, many of which are already approved for human use, for the pharmacologic induction of immunologic memory.
Publication types
-
Research Support, N.I.H., Intramural
MeSH terms
-
CD8-Positive T-Lymphocytes* / drug effects
-
CD8-Positive T-Lymphocytes* / immunology
-
Cancer Vaccines / chemistry
-
Cancer Vaccines / immunology
-
Humans
-
Immunologic Memory* / drug effects
-
Immunologic Memory* / immunology
-
Immunosuppressive Agents / chemistry
-
Immunosuppressive Agents / immunology
-
Immunosuppressive Agents / therapeutic use
-
Intracellular Signaling Peptides and Proteins / immunology
-
Protein Serine-Threonine Kinases / immunology
-
Signal Transduction / drug effects
-
Signal Transduction / physiology
-
Sirolimus / chemistry
-
Sirolimus / immunology
-
Sirolimus / therapeutic use
-
T-Lymphocyte Subsets* / drug effects
-
T-Lymphocyte Subsets* / immunology
-
TOR Serine-Threonine Kinases
Substances
-
Cancer Vaccines
-
Immunosuppressive Agents
-
Intracellular Signaling Peptides and Proteins
-
MTOR protein, human
-
Protein Serine-Threonine Kinases
-
TOR Serine-Threonine Kinases
-
Sirolimus